8-K – Page 391 – China Stock Advice

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT

[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company believes that Executive provides unique advisory and management services for the Company and wishes to retain the continued services of Executive as its Chief Executive Officer; and WHEREAS, the Company and Executive have reached an understanding with respect to Executive’s continuing employment with the Company for a] [EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] []

By info| 2016-03-27T16:21:01+00:00 March 13th, 2014|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 2014-03-13, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE March 12, 2014 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013 -- FY13 Total Sales Up 10.0% to $203.4 Million -- -- FY13 Operating Margin Up 240 Basis Points to 42.7% -- -- FY13 Non-GAAP Net Income Up 22.9% to $59.0 Million -- -- Issues FY14 Forecast -- BEIJING, China – March 12,] []

By info| 2016-03-25T06:37:13+00:00 March 12th, 2014|Categories: CBPO, Chinese Stocks, SEC Original|Tags: 0001369868, 2014-03-12, 2836, 8-K, BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES), CBPO|0 Comments

CBPO [China Biologic Products] 8-K: FOR RELEASE March 12, 2014 China Biologic Reports

[FOR RELEASE March 12, 2014 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013 -- FY13 Total Sales Up 10.0% to $203.4 Million -- -- FY13 Operating Margin Up 240 Basis Points to 42.7% -- -- FY13 Non-GAAP Net Income Up 22.9% to $59.0 Million -- -- Issues FY14 Forecast -- BEIJING, China – March 12,] []

By info| 2016-03-25T06:38:16+00:00 March 12th, 2014|Categories: CBPO, Chinese Stocks, Webplus ver|Tags: 0001369868, 2014-03-12, 2836, 8-K, BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES), CBPO|0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC.

[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By info| 2016-03-28T18:41:02+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2014-03-10, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By info| 2016-03-28T18:40:05+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 2014-03-10, 2834, 8-K, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

CNET [ChinaNet Online] 8-K: (Original Filing)

[ChinaNet Online Holdings Regain Compliance with NASDAQ Minimum Bid Price Rule BEIJING, March 10, 2014 -- ChinaNet Online Holdings, Inc. (Nasdaq Capital Market: CNET) (the “ChinaNet” or "Company"), a leading B2B (business to business) Internet technology company focusing on providing online-to-offline ("O2O") sales channel expansion services for small and medium-sized enterprises (“SMEs”) and entrepreneurial management and networking services for entrepreneurs] []

By info| 2016-03-29T23:28:17+00:00 March 10th, 2014|Categories: Chinese Stocks, CNET, SEC Original|Tags: 0001376321, 2014-03-10, 7311, 8-K, CNET, SERVICES-ADVERTISING AGENCIES|0 Comments

MONT [MONTAGE TECHNOLOGY] 8-K: (Original Filing)

[MONTAGE TECHNOLOGY ANNOUNCES RECEIPT OF NON-BINDING PROPOSAL TO ACQUIRE THE COMPANY AT US$21.50 PER SHARE SHANGHAI, China March 10, 2014 Company Contact: Montage Technology Mark Voll, CFO P: 408-982-2780 or 86-21-6128-5678 x8616 ir@montage-tech.com E: Investor Relations Contact: Shelton Group Leanne Sievers, EVP P: 949-224-3874 lsievers@sheltongroup.com E: Matt Kreps, Managing Director P: 972-239-5119 ext. 125 mkreps@sheltongroup.com E: Preliminary Non-Binding Proposal] [Item 8.01 Other Events. Item 9.01 99.1 Press Release dated March 10, 2014]

By info| 2016-03-20T02:06:42+00:00 March 10th, 2014|Categories: Chinese Stocks, MONT, SEC Original|Tags: 0001375514, 2014-03-10, 3674, 8-K, MONT, SEMICONDUCTORS and RELATED DEVICES|0 Comments

MONT [MONTAGE TECHNOLOGY] 8-K: MONTAGE TECHNOLOGY ANNOUNCES RECEIPT OF NON-BINDING PROPOSAL TO

[MONTAGE TECHNOLOGY ANNOUNCES RECEIPT OF NON-BINDING PROPOSAL TO ACQUIRE THE COMPANY AT US$21.50 PER SHARE SHANGHAI, China March 10, 2014 Company Contact: Montage Technology Mark Voll, CFO P: 408-982-2780 or 86-21-6128-5678 x8616 ir@montage-tech.com E: Investor Relations Contact: Shelton Group Leanne Sievers, EVP P: 949-224-3874 lsievers@sheltongroup.com E: Matt Kreps, Managing Director P: 972-239-5119 ext. 125 mkreps@sheltongroup.com E: Preliminary Non-Binding Proposal] [Item 8.01 Other Events. Item 9.01 99.1 Press Release dated March 10, 2014]

By info| 2016-03-20T02:07:53+00:00 March 10th, 2014|Categories: Chinese Stocks, MONT, Webplus ver|Tags: 0001375514, 2014-03-10, 3674, 8-K, MONT, SEMICONDUCTORS and RELATED DEVICES|0 Comments

EGT [Entertainment Gaming Asia] 8-K: (Original Filing)

[CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com 312/867-0848 RESULTS AND PROVIDES MARKET UPDATE ENTERTAINMENT GAMING ASIA INC. REPORTS FOURTH QUARTER AND 2013 FISCAL YEAR Hong Kong – March 6, 2014 – Entertainment Gaming Asia Inc. (NASDAQ: EGT) (“Entertainment Gaming Asia” or “the Company”), a leading gaming company focused on emerging gaming markets in Pan-Asia, today reported operating results for] [ENTERTAINMENT GAMING ASIA INC. Nevada 001-32161 91-1696010 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification Number) Unit C1, Ground Floor, Koon Wah Building No. 2 Yuen Shun Circuit Yuen Chau Kok, Shatin New Territories, Hong Kong SAR + 852-3147-6600 Not applicable (Former name or former address, if changed since last report) o o o o Item 2.02 Results of]

By info| 2016-04-02T06:12:21+00:00 March 6th, 2014|Categories: Chinese Stocks, EGT, SEC Original|Tags: 0001004673, 2014-03-06, 3990, 8-K, EGT, MISCELLANEOUS MANUFACTURING INDUSTRIES|0 Comments

EGT [Entertainment Gaming Asia] 8-K: CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com

[CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com 312/867-0848 RESULTS AND PROVIDES MARKET UPDATE ENTERTAINMENT GAMING ASIA INC. REPORTS FOURTH QUARTER AND 2013 FISCAL YEAR Hong Kong – March 6, 2014 – Entertainment Gaming Asia Inc. (NASDAQ: EGT) (“Entertainment Gaming Asia” or “the Company”), a leading gaming company focused on emerging gaming markets in Pan-Asia, today reported operating results for] [ENTERTAINMENT GAMING ASIA INC. Nevada 001-32161 91-1696010 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification Number) Unit C1, Ground Floor, Koon Wah Building No. 2 Yuen Shun Circuit Yuen Chau Kok, Shatin New Territories, Hong Kong SAR + 852-3147-6600 Not applicable (Former name or former address, if changed since last report) o o o o Item 2.02 Results of]

By info| 2016-04-02T06:13:18+00:00 March 6th, 2014|Categories: Chinese Stocks, EGT, Webplus ver|Tags: 0001004673, 2014-03-06, 3990, 8-K, EGT, MISCELLANEOUS MANUFACTURING INDUSTRIES|0 Comments